Mitchell Young Williams Sells 23,810 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) CIO Mitchell Young Williams sold 23,810 shares of Biosig Technologies stock in a transaction on Monday, June 1st. The shares were sold at an average price of $1.05, for a total transaction of $25,000.50. Following the completion of the sale, the executive directly owned 3,013,838 shares of the company’s stock, valued at approximately $3,164,529.90. The trade was a 0.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mitchell Young Williams also recently made the following trade(s):

• On Friday, May 1st, Mitchell Young Williams sold 263,863 shares of Biosig Technologies stock. The shares were sold at an average price of $0.79, for a total transaction of $208,451.77.

Biosig Technologies Stock Performance

STEX stock opened at $1.07 on Thursday. Biosig Technologies, Inc. has a 1 year low of $0.70 and a 1 year high of $14.11. The firm has a fifty day simple moving average of $1.10. The firm has a market cap of $194.53 million, a price-to-earnings ratio of -0.11 and a beta of 1.85.

Biosig Technologies (NASDAQ:STEX) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. Needham & Company LLC reduced their price objective on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, May 21st. Finally, Weiss Ratings raised shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.